Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596987 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL6449941 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL7292779 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL17286185 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL1149061 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL19460948 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL26634879 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL18604607 | 1.00 | TDP1 (0.71) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL229087 | 0.98 | TDP1 (0.68) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL7434 | 0.92 | TDP1 (0.65) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574086-B | Dicyano-isophorone derivative, preparation method thereof and application of dicyano-isophorone derivative as near infrared fluorescent probe for detecting COX-2 | BINZHOU MEDICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-121574086-A | Dicyano-isophorone derivative, preparation method thereof and application of dicyano-isophorone derivative as near infrared fluorescent probe for detecting COX-2 | 滨州医学院 | 2026-02-27 | — | — | CN | claimed |
| CN-117417521-A | Amphiphilic polymer, polymer micelle, preparation method and application thereof | 华侨大学 | 2024-01-19 | — | — | CN | claimed |
| CN-102161688-A | Cholesterol-structure-fragment-containing biocompatible synthesis liposomes as well as preparation method and application thereof | SHANGHAI INST ORGANIC CHEM | 2011-08-24 | — | — | CN | claimed |
| CN-121574086-B | Dicyano-isophorone derivative, preparation method thereof and application of dicyano-isophorone derivative as near infrared fluorescent probe for detecting COX-2 | BINZHOU MEDICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2026107406-A1 | p53 HETEROBIFUNCTIONAL CONJUGATES AND USES THEREOF | Design Therapeutics, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122057036-A | Hypoxia-targeted hyaluronic acid nano delivery system and construction method and application thereof | 上海健康医学院 | 2026-05-19 | — | — | CN | disclosed |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4151622-B1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG | SICHUAN ACAD OF MEDICAL SCIENCES SICHUAN PROVINCIAL PEOPLES HOSPITAL (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12616753-B2 | HSP70 inhibitors and methods of using same | THE WISTAR INSTITUTE (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-5292756-A | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | disclosed |
| WO-1993019046-A1 | NOVEL SULFONAMIDE FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1993-09-30 | — | — | WO | disclosed |
| US-5217994-A | METHOD OF INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION BY ADMINISTRATION OF AMINOALKYL-SUBSTITUTED PHENYL DERIVATIVES | MERCK & CO., INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5204350-A | Treating osteoporosis | MERCK & CO., INC. (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0528587-A1 | Inhibiting osteoclast-mediated bone resorption using substituted phenyl derivatives | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0528586-A1 | Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl derivatives | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0478328-A1 | Novel fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0478363-A2 | Novel sulfonamide fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | TDP1 2369/4885MAOA 4845/4885MAOB 4731/4885 |
| US-12616753-B2 | HSP70 inhibitors and methods of using same | HSPB1, HSP90AB1, HSF1 | TDP1 846/4885MAOA 3211/4885MAOB 3094/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TDP1 3694/4885MAOA 1115/4885MAOB 1349/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | TDP1 3880/4885MAOA 1793/4885MAOB 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.